Key Drivers
- Strong liquidity
- Heavy cash burn
- No revenue
AIAI Summary
IMNM has shifted from a speculative pre-commercial biotech to a near-term, binary catalyst story on varegacestat NDA/ASCO data, but with no meaningful revenue, heavy cash burn, and concentration in one asset, the stock likely hinges on regulatory execution before dilution and commercial risk re-rate the valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Heavy cash burn
- •No revenue
IMNM has an exceptionally strong cash position and low leverage, but its lack of revenue, deep losses, heavy cash burn, and extreme valuation multiples make it a highly risky, unprofitable business.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •Support holding
- •Rallies fading
IMNM is trading near the bottom of its last month range in a clear downtrend, with support around $20.90 still holding but repeated failed bounces into $22.00-$22.50 keeping the short-term bias negative.
Brief rebound from
Sentiment & News
Key News Insights:
- •NDA filing
- •Phase 3 visibility
- •Hiring expansion
Immunome is advancing varegacestat with an FDA NDA filing and ASCO presentation for Phase 3 data, while also expanding its workforce and reporting Q1 progress.
The news is incrementally positive for Immunome, as it highlights late-stage regulatory momentum and broader operational buildout
Similar Companies in Healthcare
Other companies in the same sector with AI ratings